| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1016/J.METABOL.2010.09.003 |
| P698 | PubMed publication ID | 21040935 |
| P50 | author | Stergios A. Polyzos | Q37828402 |
| Christos Zavos | Q37828411 | ||
| Dimitrios G Goulis | Q58860418 | ||
| Jannis Kountouras | Q90301782 | ||
| P2093 | author name string | Konstantinos A Toulis | |
| P433 | issue | 3 | |
| P921 | main subject | meta-analysis | Q815382 |
| liver disease | Q929737 | ||
| systematic review | Q1504425 | ||
| metabolic dysfunction–associated steatotic liver disease | Q1546498 | ||
| fatty liver disease | Q6058862 | ||
| P304 | page(s) | 313-326 | |
| P577 | publication date | 2010-10-30 | |
| P1433 | published in | Metabolism | Q15764354 |
| P1476 | title | Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis | |
| P478 | volume | 60 |
| Q51351889 | A novel appetite peptide, nesfatin-1 in patients with non-alcoholic fatty liver disease. |
| Q92671953 | A simple method for inducing nonalcoholic steatohepatitis with fibrosis |
| Q35408626 | AdipoQ T45 G and G276 T Polymorphisms and Susceptibility to Nonalcoholic Fatty Liver Disease Among Asian Populations: A Meta-Analysis and Meta-Regression. |
| Q41573222 | Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions |
| Q34779049 | Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. |
| Q38188874 | Adipokines, vascular wall, and cardiovascular disease: a focused overview of the role of adipokines in the pathophysiology of cardiovascular disease |
| Q36433571 | Adiponectin Levels Differentiate Metabolically Healthy vs Unhealthy Among Obese and Nonobese White Individuals |
| Q35971216 | Adiponectin action: a combination of endocrine and autocrine/paracrine effects. |
| Q57256784 | Adiponectin negatively correlates with alcoholic and non-alcoholic liver dysfunction: Health check-up study of Japanese men |
| Q38071935 | Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease |
| Q38017897 | Adiponectin: mechanistic insights and clinical implications |
| Q37408884 | Adipose tissue dysfunction increases fatty liver association with pre diabetes and newly diagnosed type 2 diabetes mellitus |
| Q52631894 | Association Between Nonalcoholic Fatty Liver Disease and Severe Male Reproductive Organ Impairment (Germinal Epithelial Loss): Study on a Mouse Model and on Human Patients. |
| Q55379918 | Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease. |
| Q47420892 | Association of adulthood weight gain with circulating adipokine and insulin resistance in the Japanese population |
| Q38644618 | Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review |
| Q28080541 | Biomarkers in nonalcoholic fatty liver disease |
| Q64231858 | BuShenKangShuai Tablet Alleviates Hepatic Steatosis via Improving Liver Adiponectin Resistance in ApoE Mice |
| Q31079099 | Central nervous system regulation of eating: Insights from human brain imaging |
| Q35788887 | Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis |
| Q33363300 | Combined Adiponectin Deficiency and Resistance in Obese Patients: Can It Solve Part of the Puzzle in Nonalcoholic Steatohepatitis. |
| Q38466831 | Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful? |
| Q38313076 | Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. |
| Q91471315 | Crude extract of Camellia oleifera pomace ameliorates the progression of non-alcoholic fatty liver disease via decreasing fat accumulation, insulin resistance and inflammation |
| Q92565362 | Cyclocarya paliurus Triterpenoids Improve Diabetes-Induced Hepatic Inflammation via the Rho-Kinase-Dependent Pathway |
| Q61811320 | Decreased lung function is associated with risk of developing non-alcoholic fatty liver disease: A longitudinal cohort study |
| Q37040722 | Differences in innate immune signaling between alcoholic and non-alcoholic steatohepatitis |
| Q60462153 | Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease |
| Q38827586 | Emerging and future therapies for nonalcoholic steatohepatitis in adults |
| Q58773071 | Enhancement of Adiponectin Ameliorates Nonalcoholic Fatty Liver Disease via Inhibition of FoxO1 in Type I Diabetic Rats |
| Q38207111 | Evolving therapies for non-alcoholic steatohepatitis. |
| Q58752049 | Exploration of serum sensitive biomarkers of fatty liver in dairy cows |
| Q37146192 | Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review |
| Q37362755 | Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. |
| Q84449591 | Hepatic progenitor cells: Another piece in the nonalcoholic fatty liver disease puzzle |
| Q47912507 | Impaired peripheral insulin sensitivity in non-obese Japanese patients with type 2 diabetes mellitus and fatty liver. |
| Q41694135 | Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets |
| Q57810137 | Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD |
| Q34168368 | Liver and muscle in morbid obesity: the interplay of fatty liver and insulin resistance. |
| Q34942815 | Liver function parameters in hip fracture patients: relations to age, adipokines, comorbidities and outcomes |
| Q37331309 | Low prepregnancy adiponectin concentrations are associated with a marked increase in risk for development of gestational diabetes mellitus. |
| Q58616863 | Low serum adiponectin is a predictor of progressing to nonalcoholic fatty liver disease |
| Q37615756 | Major components of metabolic syndrome and adiponectin levels: a cross-sectional study. |
| Q38365276 | Management and diagnosis of fatty liver disease |
| Q58553707 | Meta-Analysis of Adiponectin as a Biomarker for the Detection of Metabolic Syndrome |
| Q47296686 | Metabolic Profiling of Adiponectin Levels in Adults: Mendelian Randomization Analysis |
| Q28067490 | Metabolic aspects of adult patients with nonalcoholic fatty liver disease |
| Q33755566 | Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH) |
| Q57807657 | Molecular pathways of nonalcoholic fatty liver disease development and progression |
| Q27007515 | Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH) |
| Q39393326 | New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). |
| Q26852019 | Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment |
| Q35237307 | Non-alcoholic fatty liver disease and psoriasis: So far, so near |
| Q36398993 | Non-alcoholic fatty liver disease severity, central fat mass and adinopectin: a close relationship |
| Q90185419 | Nonalcoholic fatty liver disease in women with polycystic ovary syndrome |
| Q42695154 | Nonalcoholic fatty liver disease: Evolving paradigms. |
| Q38859044 | Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? |
| Q30435948 | Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease |
| Q30355082 | Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease. |
| Q26992054 | Nonmedicinal interventions in nonalcoholic fatty liver disease |
| Q38229961 | Obesity and the liver: nonalcoholic fatty liver disease |
| Q38137369 | Obesity and thyroid cancer: epidemiologic associations and underlying mechanisms |
| Q33628222 | Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines |
| Q38860270 | Obesity-induced hypoadiponectinaemia: the opposite influences of central and peripheral fat compartments |
| Q37532228 | Outcome of phlebotomy for treating nonalcoholic fatty liver disease: A systematic review and meta-analysis |
| Q64249695 | Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview |
| Q90300458 | Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study |
| Q36566846 | Prediction of Nonalcoholic Fatty Liver Disease Via a Novel Panel of Serum Adipokines |
| Q33886918 | Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis |
| Q94452875 | Radix Polygoni Multiflori and Its Main Component Emodin Attenuate Non-Alcoholic Fatty Liver Disease in Zebrafish by Regulation of AMPK Signaling Pathway |
| Q38665591 | Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines |
| Q44993268 | Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis |
| Q49144853 | Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity |
| Q33719929 | Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease |
| Q64060955 | Resistance to visceral obesity is associated with increased locomotion in mice expressing an endothelial cell-specific fibroblast growth factor 1 transgene |
| Q90292564 | Role of Soluble Adiponectin Receptor 2 in Non-Alcoholic Fatty Liver Disease in Children |
| Q38333417 | Role of adaptive immunity in alcoholic liver disease |
| Q36129432 | Role of ceramides in nonalcoholic fatty liver disease |
| Q50136712 | Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches |
| Q37616138 | Serum Cytokeratin-18 Is Associated with NOX2-Generated Oxidative Stress in Patients with Nonalcoholic Fatty Liver |
| Q53089980 | Serum total adiponectin level and risk of cardiovascular disease in Han Chinese populations: a meta-analysis of 17 case-control studies. |
| Q40707324 | Should visceral fat, strictly linked to hepatic steatosis, be depleted to improve survival? |
| Q92155088 | Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover |
| Q37001197 | The Correlation Between Serum Adipokines and Liver Cell Damage in Non-Alcoholic Fatty Liver Disease |
| Q34382081 | The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls |
| Q55450597 | The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease. |
| Q49190671 | The adipokines in the pathogenesis and treatment of nonalcoholic fatty liver disease |
| Q33945331 | The adiponectin receptor homologs in C. elegans promote energy utilization and homeostasis |
| Q38658136 | The association of non-alcoholic fatty liver disease with lung function: A survey design analysis using propensity score |
| Q100994717 | The metabolic basis of nonalcoholic steatohepatitis |
| Q39404632 | The promoting effect of adiponectin in hepatocellular carcinoma |
| Q54468632 | Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway. |
| Q89110155 | Underrated enemy - from nonalcoholic fatty liver disease to cancers of the gastrointestinal tract |
| Q36616784 | What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? |
Search more.